塞利尼索联合硼替佐米地塞米松对比硼替佐米地塞米松治疗经治多发性骨髓瘤:按细胞遗传学风险分层的结果
BOSTON 3期研究事后分析按细胞遗传学风险分层,比较每周一次塞利尼索联合硼替佐米地塞米松(XVd)与每周两次硼替佐米地塞米松(Vd)方案。高危组XVd中位PFS 12.91个月 vs Vd 8.61个月(HR 0.73,p=0.082),ORR 78.6% vs 57.7%(OR 2.68,p=0.004);标危组中位PFS 16.62 vs 9.46个月(HR 0.61,p=0.004),ORR 75.2% vs 64.7%(OR 1.65,p=0.033)。两亚组安全性均与总体人群一致。
要点
- 高危细胞遗传学患者中,XVd方案较Vd提高ORR(78.6% vs 57.7%),PFS有获益趋势。
- 标危细胞遗传学患者中,XVd方案较Vd显著改善PFS和ORR。
- 两亚组安全性均与总体人群一致。
核心结论
- 提示塞利尼索联合方案可为多发性骨髓瘤患者带来获益,无论细胞遗传学风险高低。
研究设计与样本
- BOSTON 3期研究事后分析,纳入既往接受1-3线治疗的多发性骨髓瘤患者,随机分配至XVd或Vd组。
主要发现
- 高危组:XVd中位PFS 12.91个月 vs Vd 8.61个月(HR 0.73,95%CI 0.4673-1.1406,p=0.082)。
- 高危组:XVd ORR 78.6% vs Vd 57.7%(OR 2.68,p=0.004)。
- 标危组:XVd中位PFS 16.62个月 vs Vd 9.46个月(HR 0.61,p=0.004)。
- 标危组:XVd ORR 75.2% vs Vd 64.7%(OR 1.65,p=0.033)。
- 两亚组中XVd与Vd的安全性特征均与总体人群一致。
关键数值与推荐
- 高危细胞遗传学定义:存在del(17p)、t(4;14)、t(14;16)或amp1q21≥4拷贝。
临床怎么用
- 对于经治多发性骨髓瘤患者,无论细胞遗传学风险状态,可考虑XVd方案,但高危组PFS差异未达统计学显著。
局限性
- 本分析为BOSTON研究的事后亚组分析,高危组样本量有限(141例),PFS结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1-3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone (Vd). Compared with Vd, XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy, with trends in overall survival (OS) favoring XVd. In BOSTON, 141 (35.1%) patients had MM with high-risk (presence of del[17p], t[4;14], t[14;16], or ≥4 copies of amp1q21) cytogenetics (XVd, n = 70; Vd, n = 71), and 261 (64.9%) exhibited standard-risk cytogenetics (XVd, n = 125; Vd, n = 136). Among patients with high-risk MM, median PFS was 12.91 months for XVd and 8.61 months for Vd (HR, 0.73 [95% CI, (0.4673, 1.1406)], p = 0.082), and ORRs were 78.6% and 57.7%, respectively (OR 2.68; p = 0.004). In the standard-risk subgroup, median PFS was 16.62 months for XVd and 9.46 months for Vd (HR 0.61; p = 0.004), and ORRs were 75.2% and 64.7%, respectively (OR 1.65; p = 0.033). The safety profiles of XVd and Vd in both subgroups were consistent with the overall population. These data suggest that selinexor can confer benefits to patients with MM regardless of cytogenetic risk. ClinicalTrials.gov identifier: NCT03110562.
引用
- Richard S, Chari A, Delimpasi S, et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol. 2021. PMID: 34062004. doi:10.1002/ajh.26261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。